Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Circadian Changes in the Pharmacokinetics of Acebutolol Orally Administered to Rabbits

  • Published : 2008.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

Circadian variations of acebutolol and its main metabolite, diacetolol pharmacokinetics were studied after a single oral administration of acebutolol (10 mg/kg) to eight rabbits at 10 : 00 AM (in the morning) and 10 : 00 PM (at night). The plasma concentration profiles of acebutolol were significantly different (P<0.05) between 10 : 00 AM and 22 : 00 PM, suggesting circadian variations of pharmacokinetic behaviors. A significant circadian rhythm of pharmacokinetic parameters was noted in rabbits, showing higher total body clearance (CL/F), and lower the area under the plasma concentration-time curves (AUC) of acebutolol than that at night. The half-life ($t_{1/2}$) of acebutolol and diacetolol were also significantly shorter in the morning than at night (P<0.05). Metabolite-parent AUC ratio at night significantly decreased compared to in the morning, implying that night time could inhibit acebutolol metabolism than in the morning. From this study there was an administration-time difference of acebutolol pharmacokinetics in the rabbits. The optimized dosing regimen of acebutolol can be decided by considering circadian rhythm so that the effective therapies are established for patients.

Keywords

References

  1. B. Lemmer, Circadian rhythm and drug delivery, J. Contr. Rel., 16, 6374 (1991)
  2. B. Lemmer, Chronophamacological aspects of PK/PD modeling, Int. J. Clin. Ther., 35, 458464 (1977)
  3. G. Labrecque, D. Beauchamp, M. Vanier and M.H. Smolensky, Chronopharmacokinetics, Pharm. News., 4, 1721 (1997)
  4. L. Lamberg, Chronotherapeutics: Implication for drug therapy, American Pharmacy., 31, 2023 (1991)
  5. P.M. Belanger, Drug metabolism, Pharm. News., 4, 2226 (1997)
  6. M.H. Smolensky and G. Labrecque, Chronotherapeutics, Pharm. News., 4, 1016 (1997)
  7. J. Clench, A. Reinberg and Z. Dziewanowska, Cancadian changes in the bioavailability and effect of indomethacin in healthy subject, Eur. J. Clin. Pharmacol., 20, 359369 (1981)
  8. T.L. Holcslaw, T.S. Miya and W.S. Bousqut, Circadian rhythm in drug action and drug metabolism in the mouse, J. Pharmacol. Exp. Ther., 195, 320332 (1975)
  9. W.J.M. Hrushesky, R. Borch and F. Levi, Circadian time dependence in cisplastin urinary kinetics, Clin. Pharmacol. Ther., 32, 330339 (1982)
  10. J.S. Choi and H.J. Park, Circadian changes in pharmacokinetics of cyclosporin in healthy volunteers, Res. Commun. Mol. Pathol. Pharmacol., 103, 109112 (1999)
  11. G.M. Kyle, K. Smolensky, J. Korczynska and J.P. Mcgoven, In recent advances in the chronobiology of allergy and immunology, M.H. Smolensky, ed, Pergamon Press. Oxford., 123- 128 (1980)
  12. P. Loiseau, B. Cenraud, R.H. Levy and R. Akbaraly, Diurnal variations in steady-state plasma concentration of valproic acid in epiletic patients, Clin. Pharmacokinet., 7, 544552 (1982)
  13. J.S. Choi, C.K. Kim and B.J. Lee, Administration-time differences in the pharmacokinetics of gentamycin intravenously delivered to human beings, Chlono. Inter., 16, 821829 (1999)
  14. G.L. Mattok and J. Mcgilveray, The effect of food intake and sleep on absorption of acetaminophen, Rev. Can. Biol., 32, 7784 (1973)
  15. B. Langner and B. Lemmer, Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects, Eur. J. Clin. Pharmacol., 33, 619-624 (1988) https://doi.org/10.1007/BF00542498
  16. A. Fujimura, Y. Kumagai, K. Sugimoto, H. Nakashima, H. Kajiyama, A. Ebihara and K. Ohashi, Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects, Eur. J. Clin. Pharmacol., 38, 133-137 (1990)
  17. J.S. Choi, S.C. Shin and J.P. Burm, Circadian changes in the pharmacokinetics of triamcinolone acetonide in rabbits, Res. Commun. Mol. Pathol. Pharmacol., 107, 233238 (2000)
  18. A. Markiewicz and K. Semenowicz, Time dependent changes in the pharmacokinetics of aspirin, J. Clin. Pharmacol. Biopharm., 32, 330339 (1982)
  19. U. Klotz and G. Ziegler, Physiologic and temporal variation in hepatic elimination of midazolam, Clin. Pharmacol. Ther., 32, 107-112 (1982) https://doi.org/10.1038/clpt.1982.133
  20. S. Nakano and I.E. Hollister, No circadian effect on nortriptyline kinetics in man, Clin. Pharmacol. Ther., 23, 199-203 (1978) https://doi.org/10.1002/cpt1978232199
  21. E.S. Vessel, C.A. Shively and G.T. Passananti, Temporal variation of antipyrine half-life in man, Clin. Pharmacol. Ther., 22, 843-852 (1977) https://doi.org/10.1002/cpt1977226843
  22. F. Alhenz-Gelas, P.F. Plouin, M.B. Ducrocq, P.E. Corvol and J. Menard, Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker acebutolol and diuretics in essential hypertension, Am. J. Med., 64, 1005-1012 (1978) https://doi.org/10.1016/0002-9343(78)90456-4
  23. M.A. Martin, C.A. Phillips and A.J. Smith, Acebutolol in hypertension a double blind trial against placebo, Br. J. Clin. Pharmcol., 6, 351-356 (1978) https://doi.org/10.1111/j.1365-2125.1978.tb00863.x
  24. P.G. Baker and J.A. Goulton, Multicentre study of a once daily dosage of acebutolol in the treatment of hypertension in general practice, J. Int. Med. Res., 7, 201-214 (1979) https://doi.org/10.1177/030006057900700307
  25. A. Roux, B. Flouvat, N. P. Chau, B. Letac and B. Lucsko, Pharmacokinetics of acebutolol after intravenous bolus administration, Br. J. Clin. Pharmacol., 9, 215-217 (1980) https://doi.org/10.1111/j.1365-2125.1980.tb05837.x
  26. A.J. Mclean, R.J. Mcnamara, P.D. Souich, M. Gibaldi and D. Lalka, Food, splanchnic blood flow and bioavailability of drugs subject to first pass metabolism, Clin. Pharmacol. Ther., 24, 510 (1978)
  27. J. Basil and R. Jordan, Pharmacological properties of diacetolol, a major metabolite of acebutolol, Eur. J. Pharmacol., 80, 47-56 (1982) https://doi.org/10.1016/0014-2999(82)90176-5
  28. B. Flouvat, A. Roux and N.P. Chau, Pharmacokinetics and bioavailability of diacetolol, the main matabolite of acebutolol, Eur. J. Clin. Pharmacol., 19, 287-292 (1981) https://doi.org/10.1007/BF00562806
  29. C.F. George and B.S. Gruchy, Elimination of drugs by active intestinal transport, J. Pharm. Pharmacol., 31, 643-644 (1979) https://doi.org/10.1111/j.2042-7158.1979.tb13613.x
  30. A.A. Gulaid, I.M. James and C. . Kaye, The Pharmacokinetics of acebutolol in man, following the oral administration of acebutolol as a single dose and during and after repeated oral dosing, Biopharm. Drug Dispos., 2, 103-114 (1981) https://doi.org/10.1002/bdd.2510020202
  31. R. Gabriel, C.M. Kaye and M.G. Sankey, Preliminary observations on the excretion of acebutolol and its acetyl matabolite in the urine and feces of man, J. Pharm. Pharmacol., 33, 386- 387 (1981) https://doi.org/10.1111/j.2042-7158.1981.tb13811.x
  32. J.N. Buskin, R.A. Upton, R. Jones and R.L. Williams, High performance liquid chromatography assay of acebutolol and its metabolites in plasma and urine, J. Chromatogr., 230, 438-442 (1982) https://doi.org/10.1016/S0378-4347(00)80496-X
  33. K. Yamaoka, Y. Tanigawara, T. Nakagawa and T. Uno, A pharmacokinetics analysis program for microcomputer, J. Pharm. Dyn., 4, 879-883 (1971)
  34. B. Lemmer, The chronopharmacology of cardiovascular medications, Ann. Rev Chronopharmacol., 2, 199-228 (1986)
  35. B. Lemmer and G. Labrecque, Chronopharmacology and chronotherapeutics: Definitions and concepts, Chronobiol. Int., 4, 319-329 (1987) https://doi.org/10.3109/07420528709083522
  36. B. Lemmer and K. Bathe, Stereospecific and circadian-phasedependent kinetic behavior of propranolol in plasma, heart, and brain of light--dark-synchronized rats, J. Cardiovasc. Pharmacol., 4, 635-44 (1982) https://doi.org/10.1097/00005344-198207000-00016
  37. B. Lemmer, K. Bathe, P.H. Lang and G. Neumann and H. Winkler, Chronopharmacology of beta-adrenergic blocking drugs: Pharmacokinetics and pharmacodynamic studies, J. Am. Coll. Toxicol., 2, 347-357 (1983) https://doi.org/10.3109/10915818309140723